We would like to inform you that the HOVON Data Center (HDC) and the HOVON Safety Desk will remain fully operational to ensure the safety of the patients included in HOVON trials.
The distribution and delivery of the study medicinal products are being closely monitored and we will inform you accordingly if any actions need to be taken.
The central laboratories are also still fully functioning.
At the moment it is possible to include patients in all active HOVON trials.
Please make sure to inform the HOVON Data Center per e-mail (firstname.lastname@example.org) if your hospital has decided to temporarily halt patient inclusion in clinical trials following the COVID-19 outbreak.
In case patient visits or study procedures cannot be performed per protocol due to the COVID-19, please document this in the patient files.
Given the situation surrounding the Corona virus, the HOVON central Office (HCB) and the HOVON Data Center (HDC) are temporarily unavailable by phone.
Please send all (urgent) question via email, these will be picked up and processed by the team as soon as possible. If you wish us to call you back, please indicate this in your message. We hope for your understanding of this situation.
For study specific questions, you can contact the concerning HOVON Trial Manager or our general e-mail address (email@example.com - Please include HOVON study number as reference). Thank you for your cooperation.
HOVON Central Office (HCB): firstname.lastname@example.org
HOVON Data Center (HDC): email@example.com
With kind regards, Marleen Breems (HOVON General Director) and Bianca Backx (manager HDC)